• PD98059: MEK Inhibition in MAPK/ERK Research

  2026-09-25

  PD98059 is a reversible MEK inhibitor used to test whether MAPK/ERK signaling contributes to cellular responses. A 2026 mouse and cell study reports that PD98059 attenuated ERK-associated UHRF1 expression and lipid accumulation after polystyrene nanoplastic exposure, while the product information also describes applications in leukemia and ischemia research.

• GSDMC Drives PDAC Stemness and Immune Evasion

  2026-09-25

  A 2024 Advanced Science study identifies GSDMC as a driver of pancreatic cancer stemness, metastasis, and immune evasion through ADAM17-dependent cleavage and nuclear activity, rather than its canonical pyroptotic function. The findings suggest that disrupting GSDMC processing or nuclear localization could make PDAC more responsive to KRASG12D inhibition and PD-1 blockade, although clinical translation remains to be established.

• Y-27632 Dihydrochloride for Microfabricated Cell Assays

  2026-09-24

  Pair a selective ROCK inhibitor with rapid, low-cost microfabrication to test how cell geometry and substrate features shape cytoskeletal responses. This practical guide separates what the reference study demonstrated from proposed Y-27632 workflows, with dose-planning and troubleshooting for reproducible assays.

• Bay 11-7821 in Inflammatory Signaling Workflows

  2026-09-24

  Use Bay 11-7821 (BAY 11-7082) to test how NF-κB contributes to cytokine output in monocyte inflammatory models, including CPSIT_0844 stimulation. This workflow pairs pathway readouts with genetic controls and viability checks to help distinguish NF-κB inhibition from broader effects on cell health.

• PD0325901: MEK Inhibitor Workflows for Cancer Research

  2026-09-23

  Use PD0325901 to test MEK-dependent signaling, connect ERK suppression to cell-cycle and apoptosis readouts, and build a controlled cancer-model workflow. Practical guidance distinguishes product-supported findings from proposed pilot conditions—and explains how a new study of translation termination can inform assay design without implying an unproven link to MEK.

• Isorhamnetin: A Mechanism-First Assay Guide

  2026-09-23

  Isorhamnetin is a flavonoid research compound for investigating oxidative stress, apoptosis, and PI3K/Akt-dependent cellular responses. This guide moves beyond a single efficacy result to show how chemical handling, orthogonal readouts, and pathway interpretation can produce more rigorous assays.

• ARID1A-Driven Resistance in Melanoma: Multi-Omics Insights

  2026-09-22

  The reference study integrates early signaling, molecular abundance, and network-level data to explain how ARID1A loss reshapes melanoma responses to BRAF/MAPK inhibition. Its identification of PRKD1, JUN, and NCK1 as resistance-associated nodes provides a focused framework for validating adaptive signaling, immune-related changes, and therapeutic vulnerabilities.

• Psoralen-Induced Cholestasis via ERK1/2

  2026-09-22

  Chen and colleagues show that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, cause cholestatic liver injury in zebrafish larvae through disrupted bile acid regulation and increased ERK1/2 phosphorylation. Pharmacological rescue with exemestane and GDC-0994 links estrogenic signaling and ERK activity to the phenotype, identifying ERK1/2 as a mechanistic target for further cholestasis research.

• Selonsertib (GS-4997) for Oxidative Stress Assays

  2026-09-21

  Use Selonsertib (GS-4997) to separate ASK1-dependent stress signaling from the broader autophagy and metabolic phenotypes observed in hepatic steatosis models. This workflow pairs selective kinase perturbation with p38/JNK, autophagic-flux, lipid-accumulation, and insulin-response readouts for more defensible mechanism studies.

• Psoralen, Isopsoralen, and ERK1/2 Cholestasis

  2026-09-21

  A 2024 Chemical Research in Toxicology study connected the phytoestrogens psoralen and isopsoralen to estrogen-like signaling, altered bile-acid regulation, and ERK1/2 activation in zebrafish larvae. Its combination of functional liver phenotyping, gene-expression analysis, phosphorylation measurements, and pharmacological rescue provides a mechanistic framework for studying phytoestrogen-associated cholestasis.

• AG-120 (Ivosidenib): From 2-HG to Assay Strategy

  2026-09-20

  AG-120 and Ivosidenib provide a precise way to connect mutant IDH1 inhibition with 2-hydroxyglutarate reduction, differentiation, and metabolic dependency. This article presents an assay-centered framework for interpreting AML responses and translating CD44-linked findings into stronger experimental designs.

• 4-Ethylphenyl Sulfate: Assay Workflows

  2026-09-19

  Learn how 4-ethylphenyl sulfate can support renal biomarker assays, metabolite-surface adsorption studies, and gut microbiota-brain interaction research. This workflow-focused guide emphasizes matrix controls, mass-spectrometry readiness, storage, and troubleshooting for more reproducible results.

• CCR5-Positive EVs in Rheumatoid Arthritis

  2026-09-18

  The reference study identifies CCR5-bearing extracellular vesicles released by rheumatoid arthritis synovial fibroblasts as active mediators of cartilage destruction, bone erosion, and NF-κB-associated inflammation. Its combined in vitro and adjuvant-induced arthritis experiments suggest that removing or pharmacologically blocking EV-associated CCR5 can reduce pathogenic signaling, while also defining important limits for translating this mechanism into therapy.

• GDC-0994: ERK1/2 Inhibitor Workflow Guide

  2026-09-18

  GDC-0994 provides a selective way to test whether ERK1/2 signaling drives tumor cell proliferation or estrogen-associated cholestatic injury. This practical guide connects target-engagement assays, zebrafish liver models, oncology workflows, and troubleshooting strategies around one experimentally tractable ERK pathway inhibitor.

• EX 527 for SIRT1 Mechanism Studies

  2026-09-17

  EX 527 (SEN0014196) enables selective interrogation of SIRT1 catalytic activity across p53, DNA-damage, vascular, and osteogenic models. Its biochemical potency and strong selectivity over SIRT2 and SIRT3 make it useful for separating SIRT1-dependent phenotypes from broader sirtuin effects.

8666 records 1/578 page Next 12345 下5页 Last page